Skip to main content
. 2011 Dec 14;44(3):191–201. doi: 10.3858/emm.2012.44.3.014

Figure 3.

Figure 3

Syringaresinol increases NO production by activating PI3K/Akt- and AMPK-dependent eNOS phosphorylation. (A) HUVECs were treated with the indicated concentrations of syringaresinol for 30 min, and the levels of phosphorylated proteins were determined by Western blot analysis. (B) The cells were treated with syringaresinol for 30 min following pretreatment with Wortmannin (Wort, 100 nM) and Compound C (Comp C, 10 µM) for 30 min. The level of p-eNOS was determined by Western blot analysis (C) HUVECs were treated with AICAR (1 mM) or syringaresinol (30 µM) for 30 min following pretreatment with Compound C (Comp C, 10 µM) for 30 min. The levels of p-AMPK and p-eNOS were determined by Western blot analysis. (D) HUVECs were treated with or without syringaresinol, Wortmannin, and Compound C. The levels of NO production were determined by the same methods as described in Figure 2. (E) Mouse aortic rings treated with the same as described in (D), and the levels of ex vivo NO production were determined by the same method as described in Figure 2. Data shown in (D) and (E) are the mean ± SD (n ≥ 4). *P < 0.05 and **P < 0.01 versus syringaresinol alone.